GlassScriptPhysician profile
Andrea Jones
NPI 1083072086
$10,071.80
in general payments reported to CMS, 2019-2025
44 companies · $2,348 in 2025
The $2,348 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,163 · 2022: $1,791 · 2023: $1,772 · 2024: $1,999 · 2025: $2,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,118.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,091.97 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,096.01 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $988.36 | 2021-2025 | |
| Lilly USA, LLC | $804.98 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $800.87 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $503.80 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $419.04 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $383.13 | 2021-2023 | Trintellix |
| Amgen INC. | $273.91 | 2021-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $225.59 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $198.82 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $192.13 | 2021-2023 | Belsomra, Steglatro |
| Supernus Pharmaceuticals, INC. | $183.37 | 2022-2023 | Qelbree |
| Amarin Pharma, INC. | $178.92 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $173.57 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.